Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Completed · Phase 3 · Has a placebo group

Conditions studied: Gastric Adenocarcinoma

In brief

The primary objective of this study is to compare the efficacy of andecaliximab (GS-5745) versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.

Key facts

Study ID
NCT02545504
Run by
Gilead Sciences
People needed
432
Starts
2015-10-13
Expected to finish
2019-05-15
Last updated by the study team
2020-05-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.